STOCK TITAN

Poseida Therapeutics, Inc. - PSTX STOCK NEWS

Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.

Poseida Therapeutics, Inc. (Nasdaq: PSTX) is a clinical-stage biopharmaceutical company that specializes in developing innovative cell and gene therapies aimed at curing certain cancers and rare diseases. The company's core focus is on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with unmet medical needs. Poseida's pipeline includes autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates, initially targeting hematological malignancies and solid tumors.

Poseida boasts best-in-class genome engineering capabilities, utilizing proprietary tools like the piggyBac™ DNA modification system, nextGEN™ CRISPR, XTN™ TALEN, and the footprint-free™ gene editing system. These tools are virus-free and offer surgical precision in gene editing, enabling the development of highly effective therapies.

Recent achievements include significant advancements in the company's lead program, P-BCMA-ALLO1, a novel BCMA-targeted allogeneic CAR-T therapy for treating relapsed/refractory multiple myeloma (RRMM). The FDA recently granted Orphan Drug Designation for P-BCMA-ALLO1, underscoring its potential to meet high unmet medical needs. Poseida is investigating this therapy in collaboration with Roche, with promising preliminary data presented at major scientific conferences.

In addition to its focus on cancer, Poseida is also advancing genetic medicines for rare diseases. The company has highlighted progress in its gene therapy pipeline, especially for conditions like Hereditary Angioedema and Hemophilia A. These programs employ fully non-viral approaches, leveraging Poseida's advanced genetic engineering and delivery platforms.

Poseida has formed strategic collaborations with industry giants like Janssen and Roche, enhancing its capacity to bring innovative therapies to market. The company also recently entered into a research collaboration with Xyphos Biosciences, a subsidiary of Astellas, to develop novel convertibleCAR® programs targeting solid tumors.

Financially, Poseida reported revenues of $28.1 million for Q1 2024, a substantial increase from the previous year, primarily driven by collaborations with Astellas and Roche. With a strong cash position and additional funding from strategic partnerships, Poseida is well-positioned to advance its pipeline and achieve key milestones in 2024 and beyond.

Learn more about Poseida Therapeutics and its groundbreaking work by visiting www.poseida.com and connecting with the company on X and LinkedIn.

Rhea-AI Summary

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage biopharmaceutical company, announced participation in two investor conferences. The Stifel 2022 Healthcare Conference is scheduled for November 16, 2022, at 10:20 am ET, while the Piper Sandler 34th Annual Healthcare Conference will take place on November 30, 2022, at 11:30 am ET. Webcasts will be available on Poseida's website, with replays accessible for 90 days post-event. Poseida focuses on innovative cell and gene therapeutics utilizing proprietary genetic engineering platforms.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
conferences
-
Rhea-AI Summary

Poseida Therapeutics announced that preclinical data for its gene therapy P-FVIII-101 will be presented at the 64th ASH Annual Meeting on December 11, 2022. The therapy targets Hemophilia A and uses a non-viral delivery system, showing sustained Factor VIII activity for over six months in mouse models. This presentation illustrates the potential for P-FVIII-101 to provide a durable treatment solution. The P-FVIII-101 program is in collaboration with Takeda, highlighting Poseida’s innovative approach to gene therapy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
none
-
Rhea-AI Summary

Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced the acceptance of two poster presentations at the ESMO I-O 2022 Annual Congress in Geneva, Switzerland, from December 7-9, 2022. The presentations will cover:

  • Development of an allogeneic CAR-T targeting MUC1-C
  • Phase 1 Study of P-BCMA-ALLO1 for Multiple Myeloma

Both sessions are scheduled for December 8, 2022, featuring leading experts from the University of California, San Francisco, and University of Maryland. The full abstracts will be available on the ESMO website on December 1, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.28%
Tags
conferences
Rhea-AI Summary

Poseida Therapeutics (PSTX) announced its participation in the Society for Immunotherapy of Cancer Annual Meeting, occurring from November 8-12, 2022. The company will present a poster detailing the ongoing Phase 1 clinical trial of P-MUC1C-ALLO1, aiming to treat advanced epithelial-derived solid tumors. This trial evaluates the safety, tolerability, and preliminary efficacy of P-MUC1C-ALLO1 and is expected to report initial data by early 2023. The presentation will be made by Dr. Jason Henry at the Boston Convention & Exhibition Center.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.29%
Tags
conferences clinical trial
-
Rhea-AI Summary

Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced that CFO Johanna Mylet will present virtually at the H.C. Wainwright 24th Annual Global Investment Conference, taking place in New York, NY from September 12-14, 2022. The on-demand session will be available starting at 7:00am ET on September 12. A replay will be accessible for 30 days post-presentation.

Poseida focuses on using proprietary genetic engineering technologies to develop next-generation cell and gene therapeutics aimed at curing diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.93%
Tags
conferences
-
Rhea-AI Summary

Poseida Therapeutics announced a strategic collaboration with Roche, securing a $110 million upfront payment to develop allogeneic CAR-T therapies for hematologic malignancies. The firm completed a public offering, generating $80.5 million, enhancing its capital structure. As of June 30, 2022, Poseida reported $142.6 million in cash, ensuring operational funding into mid-2024. Despite a net loss of $43 million for Q2 2022, the company remains focused on advancing its clinical pipeline with multiple ongoing CAR-T programs and expects initial clinical data from its trials by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
Rhea-AI Summary

Poseida Therapeutics (Nasdaq: PSTX) announced the closing of its underwritten public offering of 23 million shares at $3.50 each, generating gross proceeds of $80.5 million. This includes 3 million shares sold from the full exercise of underwriters' options. The offering was conducted under a shelf registration statement filed with the SEC. Joint book-running managers for the offering were Piper Sandler and William Blair & Company, with Cantor Fitzgerald & Co. and BTIG, LLC also participating.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.62%
Tags
-
Rhea-AI Summary

Poseida Therapeutics, priced an underwritten public offering of 20 million shares at $3.50 per share, aiming to generate approximately $70 million in gross proceeds. The offering is expected to close on August 8, 2022, and will fund the development of their innovative gene therapy platforms. Underwriters, including Piper Sandler and William Blair, have a 30-day option to purchase an additional 3 million shares. The offering will be made under a shelf registration previously filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
-
Rhea-AI Summary

Poseida Therapeutics, a clinical-stage biopharmaceutical company (Nasdaq: PSTX), has announced an underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of the shares offered. The offering is subject to market conditions and other factors, with no guarantee on its completion or terms. Piper Sandler and William Blair are leading the offering, which follows a previously filed shelf registration statement with the SEC. All shares sold will be offered by Poseida.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
Rhea-AI Summary

Poseida Therapeutics (Nasdaq: PSTX) has initiated an underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the shares offered. The offering follows a previously filed Form S-3 shelf registration statement. Market conditions will influence the offering's completion and terms. Key underwriters include Piper Sandler and William Blair & Company, with additional managers from Cantor Fitzgerald and BTIG. The offering details will be available via SEC filings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags

FAQ

What is the current stock price of Poseida Therapeutics (PSTX)?

The current stock price of Poseida Therapeutics (PSTX) is $9.45 as of December 20, 2024.

What is the market cap of Poseida Therapeutics (PSTX)?

The market cap of Poseida Therapeutics (PSTX) is approximately 916.2M.

What is Poseida Therapeutics, Inc.?

Poseida Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative cell and gene therapies to cure certain cancers and rare diseases.

What are Poseida's core technologies?

Poseida utilizes proprietary non-viral gene engineering tools like piggyBac™ DNA modification system, nextGEN™ CRISPR, XTN™ TALEN, and footprint-free™ gene editing system.

What is P-BCMA-ALLO1?

P-BCMA-ALLO1 is an allogeneic CAR-T therapy targeting B-cell maturation antigen for treating relapsed/refractory multiple myeloma. It has received Orphan Drug Designation from the FDA.

Who are Poseida's strategic partners?

Poseida has formed strategic collaborations with Roche, Janssen, and Astellas' subsidiary Xyphos Biosciences.

What diseases is Poseida targeting with its gene therapies?

Poseida is developing genetic medicines for rare diseases like Hereditary Angioedema and Hemophilia A, using fully non-viral gene editing and insertion technologies.

What recent financial achievements has Poseida reported?

For Q1 2024, Poseida reported revenues of $28.1 million, driven by strategic collaborations. The company has a strong cash position and funding from partnerships.

What is Poseida's approach to gene editing?

Poseida employs non-viral, virus-free gene editing systems that offer surgical precision for silencing target genes or inserting therapeutic genes.

How can I learn more about Poseida Therapeutics?

You can visit their website at www.poseida.com and follow Poseida on X and LinkedIn for the latest updates.

What is the significance of the Orphan Drug Designation for P-BCMA-ALLO1?

The Orphan Drug Designation highlights the therapy's potential to address high unmet medical needs in treating multiple myeloma, offering clinical benefits and broader access.

What are Poseida's future plans?

Poseida plans to continue advancing its cell therapy and genetic medicine programs, leveraging strategic collaborations to bring innovative treatments to market and achieve key milestones in 2024 and beyond.

Poseida Therapeutics, Inc.

Nasdaq:PSTX

PSTX Rankings

PSTX Stock Data

916.19M
70.29M
27.64%
58.48%
4.73%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
SAN DIEGO